News

The year 2023 was a breakout year for glucagon-like peptide (GLP-1) weight-loss drugs in the medical sector, led by the popularity of Ozempic. Celebrity usage and social media exposure have caused

Consolidation in the health insurance industry has become a theme of 2023. Humana Inc. (NYSE: HUM) is reportedly in talks to merge with The Cigna Group (NYSE: CI) in a stock-and-cash deal

Johnson & Johnson (NYSE: JNJ),  Gilead Sciences Inc. (NYSE: GILD) and Bristol Myers Squibb Co. (NYSE: BMY) are among healthcare sector dividend-payers trading at low valuations relative to their

Johnson & Johnson (NYSE: JNJ),  Gilead Sciences Inc. (NYSE: GILD) and Bristol Myers Squibb Co. (NYSE: BMY) are among healthcare sector dividend-payers trading at low valuations relative to their

Sports nutritional products maker BellRing Brands Inc. (NYSE: BRBR) has seen its stock surge to new all-time highs driven by the popularity of GLP-1 weight-loss medication usage. While the name of

After two years of correction and downtrend, providing ample incentive to buyers all along the way, medical device maker Medtronic (NYSE: MDT) has finally reached its bottom, and the reversal is

Welcome to the jungle. Today's stock market is not the one you inherited from your parents or even your grandparents. In prior generations, information took a bit longer to spread across sectors

Welcome to the jungle. Today's stock market is not the one you inherited from your parents or even your grandparents. In prior generations, information took a bit longer to spread across sectors

Marketbeat's stock screening tools are a wealth of investment ideas, including the 52-week low list. Stocks trading at 52-week lows often provide oversold value ready to spring back, given the

Marketbeat's stock screening tools are a wealth of investment ideas, including the 52-week low list. Stocks trading at 52-week lows often provide oversold value ready to spring back, given the

The World Series champion Texas Rangers recently paid nice dividends for sports bettors. For stock investors, there's a different, more predictable group of dividend payers worth betting on — the

Shares of Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) are down nearly 2% after the company delivered its third-quarter earnings report. The news wasn't particularly bad, although there was a

Shares of Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) are down nearly 2% after the company delivered its third-quarter earnings report. The news wasn't particularly bad, although there was a

Shares of Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) are down nearly 2% after the company delivered its third-quarter earnings report. The news wasn't particularly bad, although there was a

Pharmaceutical stocks aren't having quite the banner year they've had in the past. Notably, two large pharmaceutical companies recently plunged to 52-week lows on their earnings results. Many

Pharmaceutical stocks aren't having quite the banner year they've had in the past. Notably, two large pharmaceutical companies recently plunged to 52-week lows on their earnings results. Many

Because earnings guidance is a company's best effort to forecast its earnings, it is a leading cause of share price movement. However, simply raising or lowering guidance is not enough to move a

Shares of Johnson & Johnson (NYSE: JNJ) slid 4.84% lower the week ending October 27, as the company’s subsidiary LTL Management is facing a raft of lawsuits pertaining to talc in its baby powder. 

Shares of Johnson & Johnson (NYSE: JNJ) slid 4.84% lower the week ending October 27, as the company’s subsidiary LTL Management is facing a raft of lawsuits pertaining to talc in its baby powder. 

Shares of AbbVie Inc. (NYSE: ABBV) have been under pressure for nearly two years because of mounting fears about the patent cliff. The patent cliff impacted the company’s results but has done

Results from Johnson & Johnson (NYSE: JNJ) and Abbott Laboratories (NYSE: ABT) foreshadow good news for MedTech investors. Both companies outperformed on the top and bottom lines, driven by broad

Abbott Laboratories (NYSE: ABT) share price has trended lower for nearly 2 years, but that trend is over. The impact of COVID on sales and the post-COVID letdown were cause enough for the market

Walgreens Boots Alliance (NASDAQ: WBA) shares are down significantly over the past two years and may fall further. The company's turnaround efforts are slowly taking hold, and the impact of

Over the last several months, many sectors, industries, and the overall market have come under pressure and experienced significant outflows and waves of selling. 

During this period, over the

Over the last several months, many sectors, industries, and the overall market have come under pressure and experienced significant outflows and waves of selling. 

During this period, over the